Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers
AssigneeUniversity of Iowa Research Foundation
InventorsDongyoul Lee, Michael K. Schultz, Mengshi Li, Nicholas Baumhover, F. Christoper Pigge
Life of this patent
Estimating the term…
Abstract
The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.
Claims3
A method of treating or imaging a cancer that expresses the somatostatin receptor subtype 2 (SSTR2), the method comprising administering a conjugate having the following formula to a subject in need thereof:
- wherein n is 2;
- and the conjugate is radiolabeled with 203Pb or 212Pb.
A method of treating or imaging a cancer that expresses the somatostatin receptor subtype 2 (SSTR2), the method comprising administering a conjugate having the following formula to a subject in need thereof:
- wherein n is 2;
- wherein the method is for treating a cancer that expresses SSTR2, the conjugate is radiolabeled with 212Pb, and the conjugate is administered in a dose of up to 150 mCi, and
- wherein the cancer is selected from the group consisting of neuroendocrine tumors, small cell lung cancer meningioma, neuroblastoma, medulloblastoma, paraganglioma, and pheochromacytoma.
Dependencies are inferred from the claim text.